Citigroup began coverage on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a research note released on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $95.00 target price on the stock.
A number of other brokerages have also recently issued reports on APGE. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 price objective on the stock. Wedbush reiterated an “outperform” rating and set a $90.00 price objective on shares of Apogee Therapeutics in a research note on Tuesday. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 price objective on the stock. Finally, Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Apogee Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $92.17.
View Our Latest Analysis on Apogee Therapeutics
Apogee Therapeutics Stock Down 0.5 %
Apogee Therapeutics (NASDAQ:APGE – Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25). As a group, analysts anticipate that Apogee Therapeutics will post -3.09 earnings per share for the current fiscal year.
Insider Activity at Apogee Therapeutics
In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 15,000 shares of the stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $48.85, for a total transaction of $732,750.00. Following the transaction, the chief executive officer now owns 1,309,487 shares in the company, valued at $63,968,439.95. This trade represents a 1.13 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Carl Dambkowski sold 3,520 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $40.69, for a total value of $143,228.80. Following the transaction, the insider now owns 252,623 shares in the company, valued at $10,279,229.87. The trade was a 1.37 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 49,195 shares of company stock worth $2,026,392. Company insiders own 36.10% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in APGE. GF Fund Management CO. LTD. bought a new position in Apogee Therapeutics during the 4th quarter worth $43,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Apogee Therapeutics during the 3rd quarter worth $71,000. Optimize Financial Inc bought a new position in Apogee Therapeutics during the 4th quarter worth $203,000. Aigen Investment Management LP acquired a new stake in shares of Apogee Therapeutics during the 4th quarter worth $216,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Apogee Therapeutics during the 4th quarter worth $219,000. Institutional investors own 79.04% of the company’s stock.
About Apogee Therapeutics
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Read More
- Five stocks we like better than Apogee Therapeutics
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 Undervalued Stocks You Can Buy at a Discount Now
- How to Use Stock Screeners to Find Stocks
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- Using the MarketBeat Dividend Yield Calculator
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.